Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opti-DOR: A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Next Previous
X
Search
Trial Profile

Opti-DOR: A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Emtricitabine (Primary) ; Tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms Opti-DOR

    • Most Recent Events

    • 10 Nov 2023 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2023 Planned initiation date changed from 1 Oct 2023 to 15 Nov 2023.
    • 26 Sep 2023 Planned initiation date changed from 1 Jul 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top